TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: non-nutritive sweetener intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy Beverage Index Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in expression of a biomarker signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Adverse Events by Relationship to the Study Product
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of SAEs, AESIs, and New Chronic Conditions
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of CD4+ T Cell Responses to the HIV Proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of participants with rupture of membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Post Operative Urinary Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Unstable angina requiring hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death (cardiac and noncardiac)
Endpoint domain: Mortality/survival
Primary endpoint: Patient Reported Change in Patellar Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient Reported Change in Subluxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient Reported Change in Recurrent Dislocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline Subjective Sleep at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from Baseline Objective Sleep at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from Baseline Subjective Sleep at 18 weeks
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from Baseline Objective Sleep at 18 weeks
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Area under the concentration time curve (AUC0-inf) of serum cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in the Major Symptom Complex (MSC) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in subjective perception of neck pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in functional capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in maximum isometric strength of neck muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Adductor strengths
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: rate of alpha-synuclein in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of polyps detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cmax of EDP-305 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of EDP-305 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC-inf in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fasting and postprandial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Pulmonary function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HOMA-IR (Insulin resistance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of pertussis vaccines protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Homogentisic Acid Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: effectiveness of the PlasmaJet instrument
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of the PlasmaJet instrument
Endpoint domain: Adverse events/effects
Primary endpoint: Successful placement of PICC line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Use of vasopressors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of DNACPR decisions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reasons for not discussing DNACPR decisions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: F1-scores classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of acute myocardial infarction (AMI) patients, whose symptoms were recognized by paramedics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients correctly diagnosed as suffering acute myocardial infarction by remote ECG interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient status at 30 days post myocardial infarction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of recurrent symptomatic VTE (DVT and fatal or non-fatal PE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: All cause of mortality
Endpoint domain: Mortality/survival
Primary endpoint: Whitely Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Patients With Adverse Events or Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Glucagon response to hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of recurrence-free patients
Endpoint domain: Mortality/survival
Primary endpoint: Ad libitum intake of the test meals - weight (g)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ad libitum intake of the test meals - calories (kcal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in inflammatory proteins in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-PT GMTs (IU/mL) at 2 years after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rates of subjects with booster response in anti-PT antibody titers at Day 28 and 2 years after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate of PT neutralizing antibody increase ≥ 4-fold at 2 years after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of Major Ipsilateral Stroke or Neurologic Death
Endpoint domain: Mortality/survival
Primary endpoint: Count of Intracranial Aneurysms Evaluated as Completely Occluded
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pupil dilation from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from minimal concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent adenomas
Endpoint domain: Mortality/survival
Primary endpoint: Biochemical indicators in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinically meaningful improvements in physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinically meaningful improvements in symptoms of FMS such as pain, fatigue, and perceived cognitive difficulties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically meaningful improvements in mood and beliefs about pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maximum tolerable dose of irinotecan in combination with etoposide, cytarabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion (ROM) of the DIP joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma control assessed by asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients achieving sustained remissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in estrogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in IGF-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mobile Apps Rating Scale (MARS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: System Usability Scale (SUS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Qualitative Interview
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Overall Vision Quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Orientation agnosia evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in International Consultation on Incontinence Questionnaire: Female Lower Urinary Tract Symptoms (FLUTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in International Consultation on Incontinence Questionnaire - Short form score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in pad weight on a standardized 30 minute pad test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area Under the Curve From Time of Dosing Extrapolated to Time Infinity (AUCinf) for Roxadustat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve From the Time of Dosing to Last Measurable Concentration (AUClast) for Roxadustat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (PK) of Maximum Observed Concentration of Roxadustat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall evaluation of the treatment acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety events reported
Endpoint domain: Adverse events/effects
Primary endpoint: Change in beta cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulinotropic effect of incretin hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in progression markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optic disc blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total antibiotic consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: IBS Global Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinically definite deterioration of filling materials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste for fatty food intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rates of ACS in 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Urinary Protein/Creatinine Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Composite of all-cause death or rehospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Pharmacokinetic Parameter (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Parameter (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Parameter (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of HIV Transmission Risk Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Treatment Emergent Adverse Event (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in radiographic progression free survival (rPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Sequence-Specific Learning Effect (active tDCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sequence-Specific Learning Effect (sham tDCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Triggering delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall incidence of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Fractional urinary sodium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in glycated hemoglobin (hemoglobin A1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in units of insulin used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone Mineral Density (spine and total)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isometric peak torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Self-reported vegetable consumption
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: evidence of ruptured membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Glutamine/Creatine and Glutamate/Creatine Ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in BOLD Activations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Liver histological improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacteremia and vegetations
Endpoint domain: Adverse events/effects
Primary endpoint: re-operation
Endpoint domain: Adverse events/effects
Primary endpoint: Injection Free Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brachial endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Parents That Complete the Memory Aid 1
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Parent Completing Collection of Adverse Event Data
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Parents Completing a Satisfaction Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disease flare rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of volociximab in combination with liposomal doxorubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and tolerability of volociximab in combination with liposomal doxorubicin
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in End Diastolic Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in End Systolic Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Acceptable Overall Image Quality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants with Hematological evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Modified Rivermead Mobility Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial sensitivity to shear rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Late Gastrointestinal Toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: accuracy of breast imaging protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychotic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Thinning of the retinal nerve fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cannabis use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of cabazitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent postoperative pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Improvement in LV dP/dTmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of Severe Oral Mucositis (WHO Grade 3 or 4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative sum learning curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with cured helicobacter infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Length of luteal phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactivity of rectal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Distribution of E. coli O-serotypes causing IED
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Distribution of E. coli O-genotypes causing IED
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Distribution of IED over clinical case definitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of development of new pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with abnormal laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Active COVID-19 Disease at Day 14
Endpoint domain: Mortality/survival
Primary endpoint: Change in Disease Severity Over 14 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with healed foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in intracranial compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to deliver greater than 80% of planned doses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Related Grade 3 or higher non-hematological toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Measurable Concentration of Gemcitabine Metabolites in Uterine Vein (dFdU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum folate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: red blood cell folate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anxiety Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in fecal incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fecal incontinence days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events related to the FENIX system
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Fecal Incontinence Quality of Life: Fecal Incontinence Quality of Life (FIQOL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Definitive treatment failure (infection recurrence)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of FSH receptor polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Eylea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum and urine concentrations of salmeterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Patient Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC(0-6) FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hypothalamic CBF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of time spent > 140 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in the Grooved Pegboard Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the 39-Item Parkinson's Disease
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life